BridgeBio Oncology Therapeutics, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 2.7 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 216.47M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models. It is also involved in the development of BBO-10203, an orally bioavailable small molecule, which is in Phase I clinical trial for the treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer; and precision oncology assets for patients with tumors. The company was incorporated in 2016 is headquartered in South San Francisco, California.
Details
| Name | BridgeBio Oncology Therapeutics, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 88 |
| Founded | 2016 |
| Ceo | Pedro Beltran |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US1079241022 |
| Cusip | 107924102 |
| Cik | 0001869105 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Dr. Pedro J. Beltran M.D., Ph.D. | Chief Executive Officer and Director |
| Dr. Neil Kumar Ph.D. | Executive Chairman |
| Dr. Frank P. McCormick Ph.D. | Co-Founder, Non-Executive Director and Chair of the Advisory Board |
| Dr. Yong Ben M.B.A., M.D. | Chief Medical and Development Officer |
| Marc Cobo | Vice President of Finance and Controller |
| Idan Elmelech M.A., M.B.A. | Chief Operating Officer |
| Aaron Chan J.D. | Vice President of Legal |
| Bin Wang Ph.D. | Senior Vice President of Drug Discovery |
| Daniel Watson Ph.D. | Senior Vice President of Chemistry, Manufacturing and Controls |
| Rui Xu Ph.D. | Senior Vice President of Drug Discovery |
Contact
| Address | 256 East Grand Avenue, Suite 104, South San Francisco, California 94080, United States |
| Phone | 650 405 4770 |
| Website | https://bbotx.com |